Home / BXP.L : LSE

AI Analysis Fundamentals Video Analysis Similar

AI Analysis

How does BXP.L make money? Does BXP.L have pricing power? What's the Earnings Whisper? Will BXP.L profit more as the business scales? What is BXP.L's management track record? Is BXP.L's current price justified?

Beximco Pharmaceuticals Limited

58.5p +$16.00 (+37.65%)

LSE · 15 Sep 2026 13:49 UTC

Previous Close

62.5p

Day Range

58.5p60p

Year Range

0.42p65p

Market Cap

260.98M

AVG Volume

76.12K

Trailing/Forward PE

6.34/5.86

PEG ratio

0.45

Dividend Yield

3.97%

Next Earnings Date

2026-12-02

Primary Exchange

London Stock Exchange

Revenue (BDT)

BXP.L Revenue (BDT) by quarter
Period	Revenue (BDT)
25 Q3	13.2B
25 Q2	14.2B
25 Q1	13.57B
24 Q2	12.3B
24 Q1	11.71B
23 Q4	11.34B
23 Q3	10.99B
23 Q2	10.9B
23 Q1	11.16B
22 Q4	10.03B

Net Income (BDT)

BXP.L Net Income (BDT) by quarter
Period	Net Income (BDT)
25 Q3	2.15B
25 Q2	2.39B
25 Q1	2.32B
24 Q2	1.83B
24 Q1	1.68B
23 Q4	1.48B
23 Q3	1.36B
23 Q2	1.43B
23 Q1	1.55B
22 Q4	979.47M

Operating Income (BDT)

BXP.L Operating Income (BDT) by quarter
Period	Operating Income (BDT)
25 Q3	2.77B
25 Q2	3.15B
25 Q1	3.08B
24 Q2	2.52B
24 Q1	2.56B
23 Q4	2.16B
23 Q3	1.98B
23 Q2	2.23B
23 Q1	2.21B
22 Q4	1.6B

EBITDA (BDT)

BXP.L EBITDA (BDT) by quarter
Period	EBITDA (BDT)
25 Q3	3.28B
25 Q2	3.15B
25 Q1	3.56B
24 Q2	2.61B
24 Q1	2.95B
23 Q4	2.26B
23 Q3	2.39B
23 Q2	2.72B
23 Q1	2.7B
22 Q4	1.78B

Cash Flows (BDT)

BXP.L Cash Flows (BDT) by quarter
Period	Cash Flows (BDT)
25 Q3	2.22B
25 Q2	784.31M
25 Q1	1.72B
24 Q2	-279.87M
24 Q1	1.39B
23 Q4	1.14B
23 Q3	1.72B
23 Q2	1.29B
23 Q1	2.2B
22 Q4	941.47M

EPS (BDT)

BXP.L EPS (BDT) by quarter
Period	EPS (BDT)
25 Q3	4.82
25 Q2	5.35
25 Q1	5.2
24 Q2	4.1
24 Q1	3.77
23 Q4	3.31
23 Q3	3.06
23 Q2	3.21
23 Q1	3.48
22 Q4	2.2

Expenses (BDT)

BXP.L Expenses (BDT) by quarter
Period	Expenses (BDT)
25 Q3	3.25B
25 Q2	5.24B
25 Q1	4.15B
24 Q2	4.36B
24 Q1	3.16B
23 Q4	3.86B
23 Q3	3.24B
23 Q2	3.13B
23 Q1	3.11B
22 Q4	3.83B

Cash & Debt (BDT)

BXP.L Cash & Debt (BDT) by quarter
Period	Cash & Debt (BDT)
25 Q3	5.15B
25 Q2	4.67B
25 Q1	3.63B
24 Q2	2.36B
24 Q1	1.31B
23 Q4	1.05B
23 Q3	1.36B
23 Q2	1.35B
23 Q1	1.54B
22 Q4	1.14B

Debt ratios

BXP.L Debt ratios by quarter
Period	Debt ratios
25 Q3	-0.16
25 Q2	0.01
25 Q1	0.07
24 Q2	0.38
24 Q1	0.08
23 Q4	0.38
23 Q3	0.63
23 Q2	0.67
23 Q1	0.77
22 Q4	1.05

Margins

BXP.L Margins by quarter
Period	Margins
25 Q3	44.17%
25 Q2	48.48%
25 Q1	46.19%
24 Q2	45.29%
24 Q1	46.17%
23 Q4	44.36%
23 Q3	43.72%
23 Q2	44.86%
23 Q1	43.74%
22 Q4	42.19%

Return on Capital

BXP.L Return on Capital by quarter
Period	Return on Capital
25 Q3	3.41%
25 Q2	3.86%
25 Q1	3.96%
24 Q2	3.41%
24 Q1	3.14%
23 Q4	2.85%
23 Q3	2.71%
23 Q2	2.92%
23 Q1	3.16%
22 Q4	2.06%

Shares Outstanding

BXP.L Shares Outstanding by quarter
Period	Shares Outstanding
25 Q3	446.11M
25 Q2	446.11M
25 Q1	446.11M
24 Q2	446.11M
24 Q1	446.11M
23 Q4	446.11M
23 Q3	446.11M
23 Q2	446.11M
23 Q1	446.11M
22 Q4	446.11M

Dividends (BDT)

BXP.L Dividends (BDT) by quarter
Period	Dividends (BDT)
Jul 26	2.32
Nov 24	3.35
Nov 23	3.17
Nov 22	3.32
Nov 21	3.97
Nov 20	1.77
Nov 19	1.13
Nov 18	1.26
Nov 17	1.24
Oct 16	0.6

Book Value Per Share (BDT)

BXP.L Book Value Per Share (BDT) by quarter
Period	Book Value Per Share (BDT)
25 Q3	141.39
25 Q2	138.86
25 Q1	131.57
24 Q2	120.21
24 Q1	120.14
23 Q4	116.34
23 Q3	113
23 Q2	109.94
23 Q1	110.26
22 Q4	106.74

Total Assets (BDT)

BXP.L Total Assets (BDT) by quarter
Period	Total Assets (BDT)
25 Q3	77.48B
25 Q2	79.2B
25 Q1	74.86B
24 Q2	73.8B
24 Q1	70.9B
23 Q4	69.34B
23 Q3	70.22B
23 Q2	70.63B
23 Q1	69.35B
22 Q4	69.16B

No video analysis for this stock yet. Request one from our team.

AI Analysis

Beximco Pharmaceuticals Limited

Video analysis: BXP.L

Similar companies